¥10 Billion in Business Profit
First written in FY2016. 2 of 7 entries say "Raised", first in FY2021-Q2. Latest entry: FY2024.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2024AchievedAnnual report
「Although some initiatives under the Medium-Term Management Plan FY25 are still in progress, all quantitative targets were achieved one year ahead of schedule.」
The Group states that all quantitative targets under the Medium-Term Management Plan FY25 were achieved one year ahead of schedule. - FY2023RaisedAnnual report
「During the current consolidated fiscal year, the Group achieved the quantitative targets in the “Medium-Term Management Plan FY25” two years ahead of schedule and therefore revised the targets upward. It will pursue key initiatives with a business EBITDA target of ¥20 billion for FY25.」
After achieving the previous ¥9 billion–¥12 billion business EBITDA target, the Group raised its FY25 target to ¥20 billion. - FY2021-Q2RaisedAnnual report
「The target for business EBITDA has been revised upward from the previous range of ¥9 billion to ¥10 billion to ¥9 billion to ¥12 billion.」
In connection with an update to the medium-term management plan, the Group raised its business EBITDA target range from ¥9 billion–¥10 billion to ¥9 billion–¥12 billion. - FY2020ReframedAnnual report
「The Group will pursue performance improvement by further strengthening the earnings power of its core businesses and developing and expanding businesses in new growth areas, with business EBITDA of ¥9 billion to ¥10 billion for the fiscal year ending March 2022, set in March 2019, serving as an interim milestone.」
The Group changed its target from ¥10 billion in business profit for the fiscal year ending March 2019 to a medium-term target of ¥9 billion to ¥10 billion in business EBITDA for the fiscal year ending March 2022, with stronger core businesses and the development and expansion of growth areas as the means of achieving it. - FY2018SoftenedAnnual report
「As a management target through the fiscal year ending March 2019, the Group pursued ¥10 billion in business profit, particularly among its staged profit targets. Specifically, the target assumed that existing businesses would grow to ¥8 billion in business profit and that M&A and new investments would generate ¥2 billion. However, the target is now expected to be missed because the Group has made growth investments in existing businesses, particularly healthcare and drug discovery, and did not undertake M&A at the anticipated scale because acquisition prices in the M&A market had risen sharply.」
The Group disclosed for the first time that the ¥10 billion business profit target for the fiscal year ending March 2019 comprised ¥8 billion from existing businesses and ¥2 billion from M&A and new investments, while explaining that the target was expected to be missed because of growth investments and higher acquisition prices. - FY2017RestatedAnnual report
「Accordingly, the Group has set a medium- to long-term target of ¥10 billion in business profit, calculated by deducting selling, general and administrative expenses from gross profit, and will work to improve performance by further strengthening the earnings power of existing businesses and developing and expanding businesses in new growth areas.」
The Group continues to pursue the medium- to long-term ¥10 billion business profit target through stronger existing businesses and the development and expansion of new growth areas. - FY2016First statedAnnual report
「Accordingly, the Group has set a medium- to long-term target of ¥10 billion in business profit and will work to improve performance by further strengthening the earnings power of existing businesses and developing and expanding businesses in new growth areas.」
The Group set a medium- to long-term business profit target of ¥10 billion, with further strengthening of existing businesses and the development and expansion of new growth areas as the means of achieving it.